19:49 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Gilead discontinues gastric cancer candidate andecaliximab

Gilead Sciences Inc. (NASDAQ:GILD) announced in its 3Q18 earnings that it discontinued development of andecaliximab for gastric cancer. The company said a Phase III trial showed a lack of benefit on the primary endpoint of...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting GM-CSF and MMP9 could help treat breast cancer in obese patients. In an obese genetic mouse model of breast cancer, white adipose tissue (WAT) levels...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
00:03 , Feb 22, 2017 |  BC Extra  |  Company News

Gilead buys Sarepta PRV, mum on plans

Gilead Sciences Inc. (NASDAQ:GILD) declined to comment on plans for the Priority Review voucher it acquired on Monday. The company paid $125 million to Sarepta Therapeutics Inc. (NASDAQ:SRPT), which gained the voucher last September when...
20:23 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

GS-5745: Development discontinued

Gilead discontinued development of subcutaneous GS-5745 to treat CD and UC. The company said GS-5745 showed "no evidence of benefit" in a double-blind, placebo-controlled, international Phase II trial in patients with moderate to severe CD....
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

GS-5745: Phase II/III discontinued

Gilead discontinued a double-blind, international Phase II/III trial evaluating 2 dosing regimens of 150 mg subcutaneous GS-5745 for 8 weeks after an interim analysis of 150 patients with moderately to severely active UC by an...